TAVIST ALLERGY/SINUS/HEADACHE
LOE ApproachingNDAORALTABLET
Approved
Mar 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAVIST ALLERGY/SINUS/HEADACHE is an oral tablet combination product approved in 2001 for symptomatic relief of allergy, sinus congestion, and headache symptoms. The specific mechanism of action and pharmacologic class are not publicly detailed in available data. This product represents a multi-symptom OTC or behind-the-counter remedy targeting common cold and allergy sufferers.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling a contracting commercial footprint and potential team rightsizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE status indicate minimal career growth opportunity on this asset. Roles remaining are primarily defensive—managing decline, protecting market share, and optimizing operational efficiency rather than driving expansion or innovation.
Brand ManagerField Sales Representative
Worked on TAVIST ALLERGY/SINUS/HEADACHE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.